Exscientia Ltd Adr Stock Working Capital
Exscientia Ltd ADR fundamentals help investors to digest information that contributes to Exscientia's financial success or failures. It also enables traders to predict the movement of Exscientia Stock. The fundamental analysis module provides a way to measure Exscientia's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Exscientia stock.
Exscientia |
Exscientia Ltd ADR Company Working Capital Analysis
Exscientia's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Exscientia Working Capital | 339.87 M |
Most of Exscientia's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Exscientia Ltd ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, Exscientia Ltd ADR has a Working Capital of 339.87 M. This is 20.15% lower than that of the Biotechnology sector and 36.9% lower than that of the Health Care industry. The working capital for all United States stocks is 77.01% higher than that of the company.
Exscientia Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exscientia's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exscientia could also be used in its relative valuation, which is a method of valuing Exscientia by comparing valuation metrics of similar companies.Exscientia is currently under evaluation in working capital category among its peers.
Exscientia Fundamentals
| Return On Equity | -0.46 | |||
| Return On Asset | -0.21 | |||
| Operating Margin | (10.66) % | |||
| Current Valuation | 346.92 M | |||
| Shares Outstanding | 130.82 M | |||
| Shares Owned By Insiders | 25.90 % | |||
| Shares Owned By Institutions | 20.80 % | |||
| Number Of Shares Shorted | 2.81 M | |||
| Price To Book | 1.95 X | |||
| Price To Sales | 37.10 X | |||
| Revenue | 20.08 M | |||
| Gross Profit | 10.25 M | |||
| EBITDA | (145.45 M) | |||
| Net Income | (145.96 M) | |||
| Cash And Equivalents | 601.89 M | |||
| Cash Per Share | 4.91 X | |||
| Total Debt | 18.92 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 9.08 X | |||
| Book Value Per Share | 1.95 X | |||
| Cash Flow From Operations | (117.6 M) | |||
| Short Ratio | 5.77 X | |||
| Earnings Per Share | (1.51) X | |||
| Price To Earnings To Growth | 0.10 X | |||
| Target Price | 4.35 | |||
| Number Of Employees | 483 | |||
| Beta | 0.84 | |||
| Market Capitalization | 633.18 M | |||
| Total Asset | 510.72 M | |||
| Retained Earnings | (110.47 M) | |||
| Working Capital | 339.87 M | |||
| Net Asset | 510.72 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Exscientia Stock
If you are still planning to invest in Exscientia ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Exscientia's history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |